Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy

Psychedelic-assisted psychotherapy (PAP) departs from conventional psychopharmacology in that a psychedelic compound is administered within a therapeutic context intended to produce an altered state that facilitates psychological exploration, with integration sessions following the drug experience. There is ongoing debate about whether clinical effects derive primarily from the acute subjective experience and psychotherapeutic context or from pharmacologic actions on well‑known neuroplasticity pathways such as 5-HT2AR, AMPA-mediated glutamatergic signalling, and BDNF/TrkB. The authors note that previous translational models in psychiatry tend to treat induced neuroplasticity as a proximate biomarker for therapeutic benefit, but this view does not account for how environmental context may shape the direction and durability of plastic changes. This paper proposes using the developmental concept of critical (sensitive) periods as a conceptual framework for understanding PAP. Specifically, Moliner and colleagues suggest that psychedelics might act as interventions that “release the brakes” on adult neural plasticity, transiently reinstating a critical-period-like state during which psychotherapeutic input can produce enduring circuit remodelling. The review highlights ocular dominance plasticity (ODP) in the visual system as a well-characterised model of critical period plasticity (CPP) whose molecular and circuit mechanisms might be informative for limbic circuits implicated in psychiatric disorders.

The extracted text does not present a formal Methods section or report a systematic search strategy; instead, the paper is a conceptual review that synthesises findings from developmental psychology, visual-system research (notably ocular dominance plasticity), and experimental studies of psychotropic and psychedelic compounds. Moliner and colleagues draw on animal models (rodent studies of monocular deprivation, amblyopia, fear extinction, and social learning) and on prior pharmacological experiments involving SSRIs, ketamine, and MDMA to build a translational argument. Because the extraction lacks details on literature selection, inclusion criteria, databases searched, or quality-assessment methods, it is not possible to classify this as a systematic review from the provided text. The authors primarily interweave mechanistic findings (molecular, cellular, and circuit-level evidence) with behavioural paradigms that operationalise critical periods, and they use illustrative experimental results to support the proposition that pharmacologic reopening of CPP combined with targeted environmental input can yield lasting recovery.

The paper summarises several strands of evidence that collectively support a CPP perspective. Sensitive periods in development are defined as windows when environmental input has outsized influence on circuit formation; deprivation during those windows can produce long-lasting deficits whereas similar events in adulthood often have less effect. Ocular dominance plasticity (ODP) in primary visual cortex (V1) is presented as the most extensively characterised example: monocular deprivation during the visual critical period produces amblyopia, whereas re-opening plasticity in adulthood and providing appropriate visual experience can reverse deficits in animal models. At the molecular and circuit level, mechanisms that gate ODP include shifts in excitatory/inhibitory balance, maturation of inhibitory interneurons, perineuronal nets, myelin-related nogo receptor signalling, and Lynx family proteins. The authors report that certain psychotropic agents can pharmacologically reinstate juvenile-like plasticity in visual cortex: chronic fluoxetine (an SSRI) was shown in adult amblyopic rats to reinstate ODP and allow recovery when paired with corrective visual experience, an effect attributed to serotonin-mediated reduction of intracortical GABAergic inhibition and increased BDNF expression. Ketamine also reopens ODP in adult animals through mechanisms that include neuregulin-1-dependent restoration of excitatory drive onto parvalbumin-positive interneurons and engagement of TrkB signalling. Translationally relevant affective-circuit findings are noted: both SSRIs and ketamine, when paired with behavioural paradigms such as fear extinction, can produce enduring loss of conditioned fear in rodents, suggestive of reopened plasticity in fear-related circuits. A rodent study of MDMA is described in which a social critical period—identified behaviourally by a peak in social reward learning and biologically by oxytocin-dependent long-term depression (LTD) in nucleus accumbens—was reopened by systemic MDMA. The effect required MDMA binding to the serotonin transporter (SERT) and led to metaplastic upregulation of oxytocin receptors; importantly, the behavioural reopening occurred only in a social context, underlining context-dependence. Regarding classical serotonergic psychedelics, the 5-HT2AR is frequently implicated in their plasticity-related effects and has been linked to aspects of developmental plasticity, but the authors acknowledge competing evidence that some psychedelic-induced plasticity may occur via 5-HT2AR-independent mechanisms. The extracted text does not report human experimental evidence that psychedelics reopen ocular dominance CPP; the question remains empirical. Finally, the authors highlight a methodological gap: current translational biomarkers (for example, visually evoked potentials) capture downstream plastic changes but are not specific assays for CPP reopening.

Moliner and colleagues interpret these converging lines of work to argue that a critical-period-plasticity framework may be useful for organising mechanistic research on PAP. They suggest that psychedelics could act as pharmacologic ‘openers’ of a transient, development-like plastic state and that psychotherapeutic input during that window would direct experience-dependent circuit remodelling—analogous to patching therapy combined with reactivated ODP in vision. The paper emphasises that inducing plasticity alone is not sufficient; a structured environmental or therapeutic intervention is required to steer the malleable circuits toward adaptive outcomes. The authors propose candidate upstream biomarkers and mechanisms worth studying in PAP, including excitatory/inhibitory balance of interneurons, perineuronal nets, myelin-related nogo receptor signalling, Lynx proteins, and related molecular regulators. They caution, however, that different critical periods (visual, social, motor, cognitive, affective) likely rely on distinct molecular machinery, so ODP may be a helpful but imperfect analogue. Evidence that MDMA’s reopening of a social CPP required social context, and that not all drugs that induce plasticity (for example cocaine) reopen useful critical periods, are used to underscore the therapeutic importance of context. Key limitations acknowledged in the text include the absence of translational assays specific to CPP, limited direct human evidence that psychedelics reopen developmental critical periods, and uncertainty about whether mechanisms characterised in visual cortex generalise to limbic circuits. The authors call for targeted translational studies to detect CPP reopening in humans and for biomarker development that differentiates CPP-specific processes from generic neuroplasticity. Finally, they frame psychedelics as research probes that could help integrate neuroscientific investigation with psychosocial context to better understand what enables or halts adaptive brain change.